Status: Not yet recruiting
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafortide and cosibelimab in patients with metastatic PDAC who progressed after SOC chemotherapy.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Arsen OsipovUpdated: Nov 19, 2025Locations: 1
Eligibility criteria
Patients must have histologically (cytology) confirmed pancreatic ductal adenoca... [+12]
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or... [+13]